Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 15, 2014. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 366,500 Ordinary Shares of 25 pence each.
- Purchase Date: May 15, 2014.
- Price Range: Highest price paid was 1,642.00 pence per share; lowest price paid was 1,634.00 pence per share.
- Treasury Holdings (Settled): 491,133,712 shares (9.18% of total issued share capital).
- Treasury Holdings (Including Unsettled): 491,500,212 shares (10.11% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,859,327,416 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 366,500 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.11% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (491,133,712 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights, noting that 10.11% of total voting rights are currently held in Treasury including unsettled trades.
- Check the share price range (1,634.00 to 1,642.00 pence) against market data for May 15, 2014.
- Review the total issued share capital excluding Treasury (4,859,327,416) for use in calculating individual shareholder notification thresholds.